Background: Previous studies evaluated associations between the CYP1A2 rs762551 polymorphism andbladder cancer risk. However, the results were inconsistent. We therefore performed a meta-analysis of thepublished case-control studies to assess in detail the association between CYP1A2 rs762551 polymorphism andbladder cancer risk. Materials and
Methods: PubMed, Embase and Web of Science were searched to identifyrelevant studies and the pooled odds ratio (OR) and 95 % confidence interval (95%CI) were calculated.
Results:A total of seven articles including 3,013 cases and 2,771 controls were finally included. Overall, a significantassociation was found between the CYP1A2 rs762551 polymorphism and bladder cancer susceptibility for CCvs AA (OR=0.82, 95% CI=0.69~0.99), but no significant associations were found for the other three models (ACvs AA: OR=0.91, 95% CI=0.81~1.02; the dominant model: OR=0.90, 95% CI=0.80~1.00; the recessive model:OR=0.84, 95% CI =0.72~1.00). In the subgroup analysis by ethnicity, we detected significant associationsbetween the CYP1A2 rs762551 polymorphism and bladder cancer susceptibility for GA vs GG (OR = 0.78,95% CI =0.64~0.96) and for the recessive model (OR=0.80, 95% CI=0.66~0.96) in Caucasians, but not forAsians.
Conclusions: The results from the meta-analysis suggested that the CYP1A2 rs762551 polymorphism isa protective factor for bladder cancer, especially in Caucasians.